BiotechTube

Macugen ® (pegaptanib sodium)

ApprovedUNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Proliferative Diabetic Retinopathy

Conditions

Proliferative Diabetic Retinopathy

Trial Timeline

Nov 1, 2007 → Feb 1, 2014

NCT ID
NCT01486771

About Macugen ® (pegaptanib sodium)

Macugen ® (pegaptanib sodium) is a approved stage product being developed by Pfizer for Proliferative Diabetic Retinopathy. The current trial status is unknown. This product is registered under clinical trial identifier NCT01486771. Target conditions include Proliferative Diabetic Retinopathy.

What happened to similar drugs?

2 of 9 similar drugs in Proliferative Diabetic Retinopathy were approved

Approved (2) Terminated (2) Active (5)
🔄Brolucizumab 6 mgNovartisPhase 3
✅LucentisNovartisApproved
✅RanibizumabNovartisApproved
❌Octreotide, 30 mg i.m. LAR formulationNovartisPhase 3
🔄Intravitreal aflibercept injection [IAI] + ShamRegeneron PharmaceuticalsPhase 3
🔄Ruxolitinib + PlaceboIncytePhase 3
🔄Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 + Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24Ocular TherapeutixPhase 3

Hype Score Breakdown

Clinical
20
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01486771ApprovedUNKNOWN

Competing Products

20 competing products in Proliferative Diabetic Retinopathy

See all competitors
ProductCompanyStageHype Score
LY2784544Eli LillyPhase 1
29
LY2784544Eli LillyPhase 1
29
Navitoclax + Ruxolitinib + CelecoxibAbbViePhase 1
33
EpcoritamabAbbViePhase 1
36
Brolucizumab 6 mgNovartisPhase 3
40
CANAKINUMAB (ILARIS®)NovartisPhase 1
21
LucentisNovartisApproved
43
RanibizumabNovartisApproved
39
Octreotide, 30 mg i.m. LAR formulationNovartisPhase 3
32
Ranibizumab 0.5 mgNovartisPhase 2
35
AUY922NovartisPhase 2
27
LucentisRochePre-clinical
22
Macugen (pegaptanib) + Macugen (Pegaptanib)PfizerPre-clinical
26
Pacritinib + Decitabine + Decitabine and Cedazuridine + AzacitidineSwedish Orphan BiovitrumPhase 2
42
Fedratinib PillBristol Myers SquibbPhase 2
39
VAC85135 + IpilimumabBristol Myers SquibbPhase 1
29
Fedratinib PillBristol Myers SquibbPhase 1
21
Fedratinib Oral Capsule 300 mg + Decitabine 20 mg/m2 + Fedratinib Oral Capsule 400 mgBristol Myers SquibbPhase 1
21
AfliberceptRegeneron PharmaceuticalsPhase 2
35
2-mg Intravitreous Aflibercept InjectionRegeneron PharmaceuticalsPhase 2/3
38